Last reviewed · How we verify
NCT06288997: tACS for MUD
TACS Intervention for Methamphetamine Addiction
NA trial testing Active transcranial alternating current stimulation in Methamphetamine Use Disorder in 70 participants. Participants enrolled and being followed up; not accepting new ones.
1 September 2025
Quick facts
| Lead sponsor | Shanghai Mental Health Center |
|---|---|
| Phase | NA |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 70 |
| Start date | 21 November 2021 |
| Primary completion | 1 September 2025 |
| Estimated completion | 31 December 2025 |
| Sites | 5 locations across China |
Drugs / interventions tested
- Active transcranial alternating current stimulation
- Sham transcranial alternating current stimulation
Conditions studied
- Methamphetamine Use Disorder — all drugs for Methamphetamine Use Disorder →
Sponsor
Shanghai Mental Health Center — full company profile →
Who can join
Adults 18 to 70, any sex, with Methamphetamine Use Disorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In 2021, nearly 296 million people worldwide used psychoactive substances, highlighting a significant need for effective interventions for disorders such as Methamphetamine Use Disorder (MUD). Despite existing treatments, including behavioral therapies and medications, the relapse rates remain high, signaling the need for more potent and targeted approaches. This clinical trial investigates high-intensity transcranial alternating current stimulation (Hi-tACS), a non-invasive method that applies 15mA electrical currents with a patented frequency of 77.5Hz to modulate brain activity. Hi-tACS has shown promise in preliminary studies for its ability to reduce drug cravings significantly by influencing brain regions crucial in addiction. The primary aim of this study is to evaluate the effectiveness of Hi-tACS in curbing cravings in individuals with MUD. As secondary objectives, the trial will also explore the potential benefits of Hi-tACS in alleviating other clinical symptoms, enhancing cognitive performance, and positively influencing brain activity. This study seeks to establish Hi-tACS as a more effective treatment option that could lead to substantially lower relapse rates for individuals with MUD.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
The potential of event-related beta oscillations as biomarkers for neuromodulatory treatment efficacy.
Habelt B. · · 2026 · PMID 41756488 · DOI 10.3389/fpsyg.2026.1779055
Verify or expand the search:
- PubMed search for NCT06288997
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Methamphetamine Use Disorder
Currently open trials in the same condition.
- NCT07226596 — Non-Abstinence Outcomes in Methamphetamine Use Disorder · NA · recruiting
- NCT07450027 — LRFN5 and OLFM4 in Methamphetamine-Induced Psychosis · recruiting
- NCT06989853 — Methamphetamine and Troriluzole · EARLY_PHASE1 · recruiting
- NCT07459244 — ECG Findings in Methamphetamine Use · recruiting
- NCT06712446 — A Pilot Study of Transcranial Magnetic Stimulation Plus Episodic Future Thinking for Methamphetamine Use Disorder · NA · recruiting
Other Shanghai Mental Health Center trials
Trials by the same sponsor.
- NCT07480408 — Neural Mechanisms of the Sensorymotor Circuit in Sensory Phenomena in OCD · NA · not yet recruiting
- NCT07479771 — tTIS Targeted of the Striatum as an Intervention for MUD Patients · NA · not yet recruiting
- NCT07472673 — Transcranial Temporal Interference Stimulation Targeted of the Amygdala as an Intervention for Alcohol Use Disorder Pati · NA · not yet recruiting
- NCT07484750 — Efficacy and Influencing Factors of Mindfulness-Based Exposure Group Therapy for OCD · NA · recruiting
- NCT07311655 — Validation of the Accuracy of an AI-Based System for Diagnosing Anxiety Disorders · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06288997 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shanghai Mental Health Center
- Last refreshed: 19 September 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06288997.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing